Heroes in Drug Discovery
This award celebrates scientists who have made significant contributions to human healthcare.
The RISE Fellows at Drew University have selected the Gilead Sciences drug discovery program of Lenacapavir as recipients of Drew University’s “Heroes in Drug Discovery” award based on the discovery and development of the first FDA approved capsid inhibitor for the prevention and treatment of HIV. AIDS remains a major health problem worldwide leading to over a million deaths annually.
Through the Heroes program, our objective is to celebrate individuals who have made significant contribution to healthcare, as well as connect them to the best and brightest science undergraduates whose passions, interests, and drive position them to be the next leaders in science research.
This event is supported by a grant from Pfizer and administered by the Independent Colleges and Universities of NJ.
Zoom link for the event: https://drew.zoom.us/j/96495164649
Past winners – Heroes in Drug Discovery
- Drs. Sheri Moores and Sylvie Laquerre and the team at Johnson & Johnson for their discovery of amivantamab, the first FDA approved bispecific antibody for the treatment of lung cancer.
- Dr. Peter Senter and the team at Seagen for their discovery and development of a portfolio antibody-drug conjugates to treat cancer patients. (2020)
- Dr. Mark Miller and the team at Vertex for the discovery and development of a combination of drugs to treat cystic fibrosis patients. (2019)
- Drs. Ann Weber and Nancy Thornberry and the team at Merck for their contributions to the discovery and development of Januvia for the treatment of type II diabetes. (2019)